SignalKorea
Boehringer Ingelheim looks to Korean biotech for next drug breakthroughs
Boehringer seeks Korean biotech partnerships for drug breakthroughs.
Context
What happened: Boehringer Ingelheim CEO Shashank Deshpande said the company aims to deepen partnerships with Korean biotech firms, citing the AimedBio antibody-drug conjugate deal as a key example.
Key numbers: AimedBio license deal worth up to $991 million, signed October last year. The molecule entered Phase 1 trials with the first patient enrolled.
Why it matters: Deshpande said Korea is no longer viewed only as a sales and marketing market, and he expects such arrangements to grow as the country's biotech sector expands and contributes to global drug development.
What changed
Boehringer Ingelheim CEO Shashank Deshpande said the company aims to deepen partnerships with Korean biotech firms, citing the AimedBio antibody-drug conjugate deal as a key example.
Why it matters
Deshpande said Korea is no longer viewed only as a sales and marketing market, and he expects such arrangements to grow as the country's biotech sector expands and contributes to global drug development.